Cited by 135Lung Cancer Research StudiesLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Open access

Fan, Yun, Zhao, Jun, Wang, Qiming, Huang, Dingzhi, Li, Xingya, Chen, Jianhua, Fang, Yong, Duan, Jianchun, Zhou, Caicun, Hu, Yanping, Yang, Haihua, Hu, Yi, Zhou, Jianying, Lin, Xiaoyan, Wang, Lifeng, Wang, Zhijie, Xu, Yanjun, Zhang, Tao, Shi, Wei, Zou, Jianjun, Wang, Jie·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2020.10.002

Open this paper in CoChat — free account Open PDF

Abstract

Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting are limited. The PASSION study (ClinicalTrials.gov identifier: NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy.Methods In stage I of the study, patients were randomized (1:1:1) to receive camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off, or 7 days on and 7 days off (six patients each cohort). On the basis of tolerability during the first 28-day cycle and efficacy data at stage I, one cohort was chosen to expand to 45 patients at stage II. The primary end point was objective response rate (ORR).Results From April 20, 2018 to March 12, 2019, a total of 59 patients were enrolled, with 47 patients in the QD cohort. In the QD cohort, confirmed ORR reached 34.0% (95% confidence interval: 20.9‒49.3), the median progression-free survival was 3.6 months, and the median overall survival was 8.4 months. Chemotherapy-sensitive and chemotherapy-resistant patients (defined as patients with disease relapse at ≥90 and <90 d after platinum-based chemotherapy, respectively) had comparable confirmed ORR (37.5% versus 32.3%), median progression-free survival (3.6 versus 2.7 mo), and median overall survival (9.6 versus 8.0 mo). Treatment-related adverse events of grade 3 or higher were reported in 43 of 59 patients (72.9%). Five patients (8.5%) discontinued because of treatment-related adverse events.Conclusions Camrelizumab plus apatinib exhibited potential antitumor activity in patients with both chemotherapy-sensitive and chemotherapy-resistant ED-SCLC who had failed platinum-based chemotherapy with an acceptable toxicity profile. This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.10.002

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Self-citation
Tumor Angiogenesis
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 2,011
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database
Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844

Flagged first, then by citations

Show all 39 references

Sorted by citations

Items 101–135 of 135

Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial
Wang, W., Wu, G., Luo, W., Lin, L., Zhou, C., Yao, G., Chen, M., Wu, X., Chen, Z., Ye, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12954-8 · Cited by 2
Self-citation
The efficacy and safety of immune checkpoint inhibitor in patients with relapsed small‐cell lung cancer: A systematic review and meta‐analysis
Xu, Y., Chen, M., Ding, Y., Guo, F., Chen, M., & Lu, T. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13552 · Cited by 2
Self-citation
The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors
Chen, Y., Lin, Y., Guan, S., Zhao, Z.-R., Lin, D., Guan, J., Zhou, C., Liu, J., Cao, X., Lin, Z., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001428 · Cited by 2
Self-citation
Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report
Zhong, L., Liu, X., Li, Z., Zhang, X., Wang, Y., & Peng, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.783158 · Cited by 2
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
Cho, B. C., Ahn, M., Nishio, M., Murakami, H., Wan-Kim, D., Kim, S., Karam, S. D., Estival, A., Lin, C.-C., Trigo, J. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100884 · Cited by 1
Immune checkpoint inhibitors combined with anti‐angiogenic therapy as second‐ or further‐line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers
Chen, T., Wang, W., Qian, Y., Wang, M., Chen, Y., Cao, Y., Hu, X., Wang, X., Li, N., Jiang, J., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70102 · Cited by 1
Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis
Yu, P., Song, X., Li, Y., Chen, X., Zhou, Y., & Jiang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1653429 · Cited by 1
Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis
Zhang, J., Guo, J.-X., Li, P., Jin, X.-Y., Wang, Y., & Zhao, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1658017 · Cited by 1
Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase II studies
Yu, S., Li, H., Lu, H., Huang, Z., Chen, K., Xu, Y., Gong, L., Xie, F., Qin, J., Yu, X., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70224 · Cited by 1
Self-citation
Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer
Canale, M., Suzzi, F., Verlicchi, A., Citarella, F., Delmonte, A., & Ulivi, P. (2026) · Biology · doi:10.3390/biology15040356 · Cited by 1
A High-Quality Nomogram for Predicting Lung Metastasis in Newly Diagnosed Stage IV Thyroid Cancer: A Population-Based Study
Wang, W., Liu, J., Xu, X., Huo, L., Wang, X., & Gu, J. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231167807 · Cited by 1
PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma
Chen, X., Li, Y., Qu, X., Ye, Y., Du, X., Zhou, R., Qu, Y., Zhu, Y.-J., & Zhang, H. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3550 · Cited by 1
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
Li, X., Xia, C., Liu, M., Liu, J., Dong, M., Zhao, H., Xu, S., Wang, D., Wei, S., Song, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843116 · Cited by 1
Self-citation
End-User Use of Data Base Query Language: Pros and Cons.
Nicholes, W. (1988) · CAUSE/EFFECT
Clinical Research Progress of Carrilizumab in Patients with Lung Cancer
成, 伟. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121756
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W. J., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06283-5
Immunotherapy for Small Cell Lung Cancer
Hızal, M., & Şendur, M. A. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_244-1
Anlotinib plus oral fluoropyrimidine S-1 in treating patients with refractory or relapsed small-cell lung cancer (SALTER TRIAL): an open-label, multicenter, single-arm, phase II trialPreprint
Wang, W., Wu, G., Luo, W., Chen, Z., Lin, L., Zhou, C., Yao, G., Chen, M., Wu, X., Ye, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4457908/v1
Self-citation
Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis
Zhai, W., Yu, Y., Wu, H., Zhang, Q., Chen, Y., Yang, Y., & Fan, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241288130
Self-citation
Deep analysis of the trials and major challenges in the first-line treatment for patients with extensive-stage small cell lung cancer
Gao, R., Wu, P., Yin, X., Zhuang, L., & Meng, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114116
Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis
Li, Y., Liang, Y., Ye, P., Chen, G., Zhang, Y., Chen, M., Xiong, W., Yang, X., & Zhang, X. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09482-x
Long-term progression-free survival in a patient with extensive-stage small-cell lung cancer following second-line therapy with anlotinib and palliative chemoradiotherapy: A case report
Zan, N., Yu, D., Zhang, X., & Lin, Z. (2025) · Science Progress · doi:10.1177/00368504251382043
Immunotherapy for Small Cell Lung Cancer
Hızal, M., & Şendur, M. A. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_244
Efficacy and safety of anlotinib combined with immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer: a meta-analysis based on real-world data
Yan, Y., Yang, X., Xu, Y. L., Wang, X., & Ji, Z. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04018-9
Self-citation
Additional file 3 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569132
Additional file 1 of Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26610165
Self-citation
Additional file 4 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569135
Additional file 2 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569129
Additional file 5 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569138
Additional file 1 of A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
Gumbleton, M., Allan, S., Conway, H., Boucher, K. M., Marvin, J., Hawks, J., Burnett, W., Brocklin, M. W. V., Whisenant, J. R., Gilcrease, G. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26569126
Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians
Hao, Z., Villano, J. L., Arnold, S. M., & Anthony, L. B. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261458324
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial
Zeng, L., Tian, F., Wang, C., Chen, Q., Jiang, W., Liang, J., Tan, Y., Yan, H., Huang, J., Zhou, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102931
Self-citation
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)
Fan, Y., Yang, R., Min, X., Ma, H., Wang, Y., Zhao, Y., Wang, H., Zhang, M., Wang, H., Zhang, T., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1879524
Self-citation
The Five-Decade Journey of Small Cell Lung Cancer
Chen, R., Xue, C., Zhong, Y., Huang, Q., Fan, Q., Li, Y., Wu, J., Dong, S., Li, X., Xiao, T., et al. (2026) · 癌症：英文版 · doi:10.34133/cancomm.0052
Self-citation
Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial
Jin, Y., Lu, W., Lou, L., Zeng, J., Fan, Y., & Chen, D. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-118036
Self-citation

Authors: Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., Yang, H., Hu, Y., Zhou, J., Lin, X., Wang, L., Wang, Z., Xu, Y., Zhang, T., Shi, W., Zou, J., & Wang, J.
Affiliations: Zhejiang Cancer Hospital (CN)
Peking University Cancer Hospital (CN)
Henan Cancer Hospital (CN)
Tianjin Medical University Cancer Institute and Hospital (CN)
First Affiliated Hospital of Zhengzhou University (CN)
Hunan Cancer Hospital (CN)
Sir Run Run Shaw Hospital (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Tongji University (CN)
Chinese PLA General Hospital (CN)
Zhejiang Taizhou Hospital (CN)
First Affiliated Hospital Zhejiang University (CN)
Union Hospital (CN)
Nanjing Drum Tower Hospital (CN)
Corresponding author: Wang, Jie
ORCID: Fan, Yun
Zhao, Jun
Wang, Qiming
Huang, Dingzhi
Li, Xingya
Chen, Jianhua
Fang, Yong
Duan, Jianchun
Zhou, Caicun
Hu, Yanping
Yang, Haihua
Hu, Yi
Zhou, Jianying
Lin, Xiaoyan
Wang, Lifeng
Wang, Zhijie
Xu, Yanjun
Zhang, Tao
Shi, Wei
Zou, Jianjun
Wang, Jie
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-02
Volume: 16
Issue: 2
Pages: 299-309
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2020.10.002
OpenAlex: W3095089286
Cited by: 135
References: 39
Citations by year: 2026: 7 · 2025: 20 · 2024: 35 · 2023: 22 · 2022: 30 · 2021: 19
FWCI: 6.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: camrelizumab, apatinib, extensive-stage small cell lung cancer, second-line therapy, PD-1 inhibitors, anti-angiogenic therapy, platinum-based chemotherapy, objective response rate, progression-free survival, overall survival, treatment-related adverse events
MeSH terms: Humans, Lung Neoplasms, Pyridines, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks